BCL2 and acute myeloid leukemia: Sensitivity to combined BCL-2/MCL1 targeting (LC50 < 100 nM) was observed across a broad spectrum of AML cases, including those with recognized poor risk genomic features, such as mutated RUNX1 (11/15 cases sensitive), DNMT3A (10/16 cases sensitive) or ASXL1 (7/14 cases sensitive)(Fig. 2) [1].